Monthly Archives: May 2017

SNMMI Comments to FDA on Compounding

Posted on May 5, 2017 by C. Kubler

SNMMI submitted comments to the FDA on draft guidance “Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies.” The guidance explains that, under current law, radiopharmaceuticals compounded or repackaged by state-licensed nuclear pharmacies and federal facilities are subject to all … Continue reading →

Posted in PET Drugs | Leave a comment